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We report a case of an asymptomatic 39-year-old male who was incidentally found to have a white blood cell count of 15000/mm3
associated with a positive BCR-ABL/t(9;22)(q34;q11) chromosomal translocation detected in 51/300 of cells by FISH and RT-
PCR from peripheral blood. Within the next 3 months, leukocytosis spontaneously subsided; however, BCR-ABL by RT-PCR and
FISH was persistent both in peripheral blood and bone marrow. The patient was not started on any therapy and is being followed
regularly with laboratory checkup and physical examination for monitoring signs and symptoms of chronic myeloid leukemia
(CML) and biological behavior of his BCR-ABL transcripts. At 1 year of surveillance, he is disease free; however he has persistent
detection of BCR-ABL fusion gene. Our case is challenging because actual risk of developing CML in BCR-ABL positive healthy,
asymptomatic patients is not known.
1.Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative
disorder with an incidence of 2 cases per 100,000 people and
represents 7–20% of all leukemia cases [1]. Although is an
uncommon entity, CML is one of the few leukemias that
has a deﬁned pathogenesis; which involves the Philadelphia
chromosome (Ph)/t(9;22)(q34;q11) chromosomal translo-
cation and activated tyrosine kinases (TK) in the mutated
hematopoietic stem cell [2]. Also, it is one of the ﬁrst
leukemias in which a rational targeted therapy with tyrosine
kinase inhibitors (TKI) revolutionized the treatment and
natural history of the disease by improving overall survival
(OS) with long term remissions [1, 3]. Although it was once
to be thought to be pathognomonic for CML, evidence of
BCR-ABL fusion gene or t(9;22)(q34;q11) translocation is
also found in approximately in one-third of cases of ALL
and <1% of AMLs [4, 5]. Moreover, there is a substantial
group of asymptomatic, healthy people who can bare this
chromosomal aberration and never develop CML [5–7].
As of now, there are no guidelines for stratiﬁcation of
the risk factors for CML development, monitoring BCR-
ABL transcripts and establishing a proper treatment in this
subgroup. We report a case of an asymptomatic 39-year-old
malewhowasfoundtohavewhitebloodcell(WBC)countof
15.000/mm3 without therapy yet, associated with a positive
BCR-ABLtranslocation andsubsequentnormalization ofhis
leukocytosis with persistence of the BCR-ABL detection in




The patient is a 39-year-old Jamaican man who was found to
have elevated WBC of 15.000/mm3 with normal diﬀerential,
asanincidentalﬁndingduringafollowupvisittohisprimary
care physician. Review of systems were negative including
fever/chills, weight loss, night sweats and bleeding. Past
medicalhistorywassigniﬁcantforhypertensionanddiabetes
mellitus type II. On physical examination, there were no
palpable enlarged lymph nodes, organomegaly or signs of
bleeding. Complete Blood Count (CBC) showed WBC of
15.000/mm3 with normal diﬀerential, hemoglobin (Hb) and
hematocrit (Htc) of 15mg/dL and 45%, and platelets of2 Case Reports in Medicine
308.000/mm3. The peripheral blood smear showed normal
neutrophils, no myelocytes, metamyelocytes, nucleated red
blood cells or giant platelets. Metaphase cytogenetic analysis
of PB did not demonstrate any karyotype abnormalities;
however BCR/ABL t(9;22) was detected in 51 of 300 cells
by Fluorescence In-Situ Hybridization (FISH) and quanti-
tative real time PCR (RT-PCR). There were no evidence
of other cytogenetic or molecular abnormalities. Further
work-up with CT-chest/abdomen/pelvis did not reveal any
systemic disease. At that time, no speciﬁc treatment was
recommended and a follow-up appointment was scheduled.
During 3 months surveillance, he had been asymp-
tomatic and physical examination was normal. A repeat
CBC showed WBC of 7600/mm3 with 78% neutrophils,
16% lymphocytes, 5.9% basophils, 3.4% monocytes without
metamyelocytes, myelocytes or any other atypical granulo-
cytes. Hb and platelets were 15.3mg/dL and 364.000/mm3,
respectively. His metabolic panel was within normal limits,
including LDH of 588 mg/Dl. Peripheral blood smear (PBS)
and ﬂow cytometry was unremarkable again. The repeat
BCR/ABL t(9;22) FISH and PCR analysis was positive.
Further work-up with bone marrow biopsy demonstrated
normocellularBMwithgranulocytesinallmaturationstages
with adequate number and normal morphology; and 2%
blasts. The M : E ratio was normal. Karyotype analysis
of bone marrow showed t(9;22) in 4 of 20 metaphases.
Furthermore, FISH for BCR/ABL t(9;22) translocation was
positive in 52% of the bone marrow cells. Currently, at
1 year of surveillance, the patient still continues being
asymptomatic without any treatment and there is no cyto-




4000 new cases diagnosed yearly in USA [8]. More than
50% of patients with CML present during the chronic
phase of the disease with ﬂorid constitutional symptoms and
signs including hepatosplenomegaly, marked leukocytosis
(usually >25.000/mm3) with or without thrombocytosis and





Although demonstration of the BCR-ABL fusion gene or
chromosomal translocation t(9;22)(q34;q11) in PB and/or
BM cells is part of the essential criteria for CML diagnosis
[2, 5], there is a signiﬁcant prevalence of positive extremely
low levels of BCR-ABL transcripts (accounting for no
more than 1–10 per 108 WBC) up to 30% of completely
asymptomatic healthy subjects with normal blood counts
[5, 6]. This observation suggests that BCR-ABL has to be
expressed in the appropriate progenitor cells in order to gain
a selective growth advantage and cause clinical disease [9].
Furthermore,Biernauxetal.[6]hasdemonstratedincreasing
incidence of positive BCR-ABL transcripts by advancing age
as transcripts were not detectable in cord blood and in only 1
of 22 children but in 18 of 52 adults. The eﬀects of age could
be explained by the fact that, in adults, there have been more
cell divisions and therefore a greater chance of accumulating
genetic lesions [6].
Our patient’s presentation leads to a complex debate
in terms of the clinical management and followup of his
“condition”. Initially, he presented with mildly elevated WBC
withno signs or symptoms of CML, butwitha positive BCR-
ABL; subsequently, his blood counts normalized without any
treatment; he remained asymptomatic, but BCR-ABL in PB
and BM persisted.
FISH is an essential technique for the cytogenetic iden-
tiﬁcation of the Ph chromosome; however, diﬀerent groups
have reported a FISH sensitivity of 98% with false positive
r e s u l t so f2 . 3t o2 . 8 %[ 10]. These low rates of false positive
detections are usually clinically non-signiﬁcant, when the
FISH analysis is backed by cytogenetic metaphase analysis
and RT-PCR of PB or BM cells. RT-PCR measures the BCR-
ABL mRNA transcripts comparing them with a housekeep-
ing gene that ideally is expressed in leukemia cells at exact
same level as in normal cells [11]. The original descriptions
ofpositiveBCR-ABLdetectionsinhealthypersonsweredone
using a exquisite sensible RT-PCR technique 40 times more
sensible that the usual clinical test [5, 6]. In our clinical case,
the patient had serial RT-PCR assessments done by diﬀerent
laboratories in a short time frame, both PB and BM were
positive; so regardless of the sensitivity of the RT-PCR, the
sequential unbiased followup decreases substantially the rate
of false positive results in his samples.
The most challenging question is the proper approach to
the treatmentand monitoring of the patient presented in our
clinical case. CML treatment has radically changed with the
introduction of TKI in 1998 [12] .T K Ih a v ed e m o n s t r a t e d
excellent responses with increase in OS and mild adverse
eﬀects[3,12].Also,ithasbeendemonstratedthattreatments
in patients with CML, including TKI like imatinib, are more
eﬀective in the chronic phase of the disease than in advanced
stages [9]. Finally but not least, it is very important to take
into account that untreated CML is characterized by the
inevitable transition from a chronic phase to an accelerated
phase and on to blast crisis in a median time of 4 years
[1]. On the other hand, since the incidence of asymptomatic
healthy individuals that harbor these aberrations exceeds by
far the incidence of CML, most positive subjects will never
develop leukemia [5, 7] and, to our knowledge there are no
guidelines or reports about the treatment of asymptomatic
patients with positive BCR-ABL fusion gene, without any
other features of CML; similar to the clinical situation
of our patient. We are facing an important therapeutic
dichotomy: should we treat the patient using his persistent
positive BCR-ABL results as the unique component of
disease, even though he has no other CML features, exposing
him to unnecessary medication adverse eﬀects, without a
deﬁned therapeutic goal or should we pursue a “watch and
wait” approach as commonly used in chronic lymphocytic
leukemia, implementing close followups including CBC,
cytogenetics, FISH and RT-PCR to monitor the evolution of
the BCR-ABL transcripts and the eventual development of a
full blown leukemia?Case Reports in Medicine 3
Since our patient is totally asymptomatic, with normal
blood counts with low persistent detection of BCR-ABL
fusion gene, the consensus was to follow him without
treatment and very close control of his cell counts with
specialattentiontohisBCR-ABLfusiongeneevolutionevery
three months, as it is usually done for CML patients in
treatment.
4. Conclusion
Asymptomatic healthy persons with t(9;22)(q34;q11) chro-
mosomal translocation are fairly common. Although there is
no long-term followup for this group of patients, given the
rarity of CML in general population, one could extrapolate
that only small portion of this population would develop
CML. To our knowledge, there has been no report of
an asymptomatic patient with persistent positive BCR-ABL
translocation and initially elevated WBC that normalized
without therapy. Currently, the biological consequences of
positive BCR-ABL in healthy persons without histological
evidence of leukemia have not been studied in detail and
there is no standard approach for treatment.
References
[1] A. Redaelli, C. F. Bell, J. Casagrande, et al., “Clinical and
epidemiologic burden of chronic myelogenous leukemia,”
Expert Review of Anticancer Therapy, vol. 4, no. 1, pp. 85–96,
2004.
[2] P. C. Nowell and D. A. Hungerford, “Chromosome studies in
human leukemia. II. Chronic granulocytic leukemia,” Journal
of the National Cancer Institute, vol. 27, pp. 1013–1035, 1961.
[3] B. J. Druker, F. Guilhot, S. G. O’Brien, et al., “Five-year
follow-up of patients receiving imatinib for chronic myeloid
leukemia,” The New England Journal of Medicine, vol. 355, no.
23, pp. 2408–2417, 2006.
[4] L. Selleri, G. Emilia, M. Luppi, et al., “Chronic myelogenous
leukemia with typical clinical and morphological features can
be Philadelphia chromosome negative and “bcr negative”,”
Hematologic Pathology, vol. 4, no. 2, pp. 67–77, 1990.
[5] S. Bose, M. Deininger, J. Gora-Tybor, J. M. Goldman, and
J. V. Melo, “The presence of typical and atypical BCR-ABL
fusion genes in leukocytes of normal individuals: biologic
signiﬁcance and implications for the assessment of minimal
residual disease,” Blood, vol. 92, no. 9, pp. 3362–3367, 1998.
[6] C. Biernaux, M. Loos, A. Sels, G. Huez, and P. Stryckmans,
“Detection of major bcr-abl gene expression at a very low level
in blood cells of some healthy individuals,” Blood, vol. 86, no.
8, pp. 3118–3122, 1995.
[7] J. B¨ asecke, F. Griesinger, L. Tr¨ umper, and G. Brittinger,
“Leukemia- and lymphoma-associated genetic aberrations in
healthy individuals,” Annals of Hematology,v o l .8 1 ,n o .2 ,p p .
64–75, 2002.
[8] C. L. Sawyers, “Chronic myeloid leukemia,” The New England
Journal of Medicine, vol. 340, no. 17, pp. 1330–1340, 1999.
[9] J. M. Goldman and J. V. Melo, “Mechanisms of disease:
chronic myeloid leukemia—advances in biology and new
approaches to treatment,” The New England Journal of
Medicine, vol. 349, no. 15, pp. 1451–1464, 2003.
[10] M. Yanagi, K. Shinjo, A. Takeshita, et al., “Simple and
reliably sensitive diagnosis and monitoring of Philadelphia
chromosome-positive cells in chronic myeloid leukemia by
interphase ﬂuorescence in situ hybridization of peripheral
blood cells,” Leukemia, vol. 13, no. 4, pp. 542–552, 1999.
[11] T. Hughes, M. Deininger, A. Hochhaus, et al., “Monitoring
CML patients responding to treatment with tyrosine kinase
inhibitors: review and recommendations for harmonizing
current methodology for detecting BCR-ABL transcripts and
kinase domain mutations and for expressing results,” Blood,
vol. 108, no. 1, pp. 28–37, 2006.
[12] B.J.Druker,M.Talpaz,D.J.Resta,etal.,“Eﬃcacyandsafetyof
a speciﬁc inhibitor of the BCR-ABL tyrosine kinase in chronic
myeloid leukemia,” The New England Journal of Medicine, vol.
344, no. 14, pp. 1031–1037, 2001.